Linaclotide Evidence Guide
Linaclotide (Linzess) is FDA-approved for IBS-C and chronic idiopathic constipation, with robust Phase 3 data across multiple trials. It is one of the most prescribed GI peptide drugs in the US, with real-world data supporting its Phase 3 results. For guanylate cyclase-C agonism and IBS-C research, linaclotide is the established reference compound.
Our Take
Linaclotide (Linzess) is FDA-approved for IBS-C and chronic idiopathic constipation, with robust Phase 3 data across multiple trials. It is one of the most prescribed GI peptide drugs in the US, with real-world data supporting its Phase 3 results. For guanylate cyclase-C agonism and IBS-C research, linaclotide is the established reference compound.
- Best for
- IBS-C, chronic idiopathic constipation, guanylate cyclase-C agonism, visceral pain modulation
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 72mcg oral daily (IBS-C); 145mcg oral daily (CIC)
Benefits and Evidence
- IBS-C Symptom Relief: Level A, includes human evidence - Large Phase 3 trials demonstrate significant improvement in both abdominal pain and complete spontaneous bowel movements. Dual efficacy on pain and constipation distinguishes it from simple laxatives.
- Chronic Idiopathic Constipation Relief: Level A, includes human evidence - Robust evidence from multiple RCTs showing increased CSBM frequency, improved stool consistency, and reduced straining in CIC patients.
- Visceral Pain Reduction: Level A, includes human evidence - Clinically meaningful reduction in abdominal pain scores independent of bowel movement improvement, mediated through cGMP effects on colonic afferent neurons.
- Diarrhea (Adverse): Level A, includes human evidence - Diarrhea is the most common side effect, occurring in approximately 16-20% of IBS-C patients at the 290 mcg dose. May lead to discontinuation in 4-5% of patients.
Side Effects and Warnings
- Diarrhea (most common, up to 20% at higher doses)
- Abdominal pain
- Flatulence
- Abdominal distension
- Upper respiratory tract infection
- Sinusitis
- Fecal incontinence (rare)
- Contraindicated in children under 2 years (risk of serious dehydration and death in neonatal mice)
Research Dosage References
- <strong>Oral</strong> - 290 mcg - Once daily - FDA-approved dose for IBS-C. Take on empty stomach at least 30 minutes before first meal of the day.
- <strong>Oral</strong> - 145 mcg - Once daily - FDA-approved dose for CIC. Can be reduced to 72 mcg if 145 mcg is not tolerated.
- <strong>Oral</strong> - 72 mcg - Once daily - Lower dose approved for CIC. May be preferred in patients sensitive to diarrhea.
Mechanism of Action
Linaclotide acts through GC-C receptor activation: 1. GC-C receptor agonism: Binds to and activates guanylate cyclase-C on the luminal surface of intestinal epithelium, elevating intracellular cGMP. 2. CFTR-mediated secretion: cGMP-dependent phosphorylation of CFTR chloride channels drives chloride, bicarbonate, and water secretion into the intestinal lumen. 3. Accelerated transit: Increased luminal fluid softens stool and accelerates colonic transit time. 4. Visceral analgesia: Extracellular cGMP released basolaterally inhibits pain-sensing colonic afferent neurons, reducing visceral hypersensitivity independently of the secretory effect. 5. Intestinal barrier support: May enhance intestinal barrier function through cGMP-mediated tight junction modulation.
Legal Status
FDA-approved (Linzess) since August 2012 for IBS-C and CIC. Marketed as Constella in Europe (EMA-approved 2012). Prescription required. Available worldwide in multiple markets.
Primary Sources
- Linaclotide for irritable bowel syndrome with constipation: two randomized, double-blind Phase 3 trials. Am J Gastroenterol, 2012.
- Linaclotide for chronic idiopathic constipation: Phase 3 efficacy and safety. Am J Gastroenterol, 2010.
- Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cGMP. Gastroenterology, 2013.